Personalis Announces the Launch of SHERPA™ for High-Accuracy Neoantigen Prediction and Cancer Diagnostic Biomarker Developm...
17 12월 2020 - 11:07PM
Business Wire
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics
for cancer, today announced the launch of its Systematic HLA
Epitope Ranking Pan Algorithm (SHERPA), the company’s proprietary,
machine learning-based tool for the comprehensive identification
and characterization of cancer neoantigens. Integrated into the
Personalis® NeXT Platform™, SHERPA enables the development of new
neoantigen-based diagnostic biomarkers, such as the company’s
proprietary Neoantigen Presentation Score (NEOPS™), and novel
personalized therapies.
Data presented at the SITC Annual Meeting in November 2020
showed SHERPA outperforming commonly used neoantigen binding
prediction tools in clinical tumor samples. “With more accurate
neoantigen presentation prediction, we are looking to enable a new
generation of precision oncology applications,” said Richard Chen,
MD, Personalis CSO. “Trained on a proprietary immunopeptidomics
dataset derived from engineered cell lines, SHERPA improves
neoantigen presentation prediction compared to other in silico
methods. With this advancement, SHERPA can enable more predictive
biomarkers for cancer therapy as well as facilitate the development
of neoantigen-targeting, personalized cancer therapies. Our
recently-launched NEOPS is one example of a SHERPA-derived
composite biomarker that has shown promise in predicting
immunotherapy response in cancer patients.”
While most conventional in silico methods generally only assess
the potential MHC-binding affinity and stability of identified
peptides, SHERPA goes a step further by incorporating features
relating to the antigen processing machinery and RNA abundance to
generate a presentation rank for each detected peptide. This serves
to determine the relative likelihood of a given neoantigen being
presented and undergoing immunosurveillance.
This launch represents the broader commercial release of SHERPA,
which is currently being leveraged by Personalis’ preferred
partner, Sarepta Therapeutics, to characterize immune response to
precision genetic therapeutics in patients with rare diseases,
demonstrating the applicability of this machine learning tool in
disease areas beyond cancer.
About Personalis, Inc.
Personalis, Inc. is a leader in cancer genomics, with a focus on
data, scale, efficiency and quality. Personalis operates one of the
largest sequencing operations globally. In oncology, Personalis is
transforming the development of next-generation therapies by
providing more comprehensive molecular data about each patient’s
cancer and immune response. The Personalis NeXT Platform is
designed to adapt to the complex and evolving understanding of
cancer, providing its biopharmaceutical customers with information
on all of the approximately 20,000 human genes, together with the
immune system, from a single tissue sample. The Personalis Clinical
Laboratory is GxP aligned as well as CLIA’88-certified and
CAP-accredited. For more information, please visit
www.personalis.com and follow Personalis on Twitter
(@PersonalisInc).
Forward-Looking Statements
All statements in this press release that are not historical are
“forward-looking statements” within the meaning of U.S. securities
laws, including statements relating to attributes or advantages of
SHERPA, NEOPS or the Personalis NeXT Platform, the company’s
business opportunities, leadership or growth, or other future
events. Such forward-looking statements involve risks and
uncertainties, including those related to the COVID-19 pandemic,
that could cause actual results to differ materially from any
anticipated results or expectations expressed or implied by such
statements. Factors that could materially affect actual results can
be found in Personalis’ filings with the U.S. Securities and
Exchange Commission, including the company’s most recent reports on
Forms 8-K, 10-K and 10-Q, and include those listed under the
caption “Risk Factors.” Personalis disclaims any obligation to
update such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201217005355/en/
Investor Relations Contact for Personalis: Caroline Corner
investors@personalis.com www.westwicke.com 415-202-5678
Media Contact for Personalis: Jennifer Havlek pr@personalis.com
www.personalis.com 650-752-1300
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024